Health technology assessment and implications for clinical practice: the case of prostate cancer screening.
We describe an initiative to disseminate evidence from systematic reviews about the clinical effectiveness of prostate cancer screening to general practitioners and urologists in Norway. The Norwegian Centre for Health Technology Assessment invited The Norwegian Medical Association, The Norwegian Cancer Society, The Norwegian Board of Health, The Norwegian Urological Cancer Group and The Norwegian Patient Association to develop and disseminate clinical practice recommendations. The clinical effectiveness of prostate cancer screening has been assessed in nine independent systematic reviews, which are summarized in a joint INAHTA report. The conclusion was that there is no evidence from appropriately designed trials that early detection and treatment of prostate cancer can reduce mortality, morbidity or improve quality of life. The number of prostate-specific antigen (PSA) tests analysed in Norway increased by 47% [corrected] from 1996 to 1999; at the county level the increase ranged from 12 to 48%. On this background we disseminated leaflets with information about PSA and prostate cancer to 4100 general practitioners and specialists in urology. The main message was, i) PSA should not be taken in healthy men, ii) if the test is wanted, the physician is obliged to give information about the possible consequences. Despite efforts to anchor the information campaign within the mentioned organizations, this met with notable opposition from The Norwegian Urological Society. A survey among agencies within the INAHTA network showed that more than half of the countries within this collaboration have implemented guidelines or recommendations on prostate cancer screening. In conclusion, evidence obtained through an international collaboration such as the INAHTA collaboration may be used to develop and implement national guidelines or recommendations.
The Norwegian Centre for Health Technology Assessment, SINTEF Unimed, Oslo, Norway. Inger.N.Norderhaug@sintef.no
I N
IN
Norderhaug
S
S
Sandberg
S D
SD
Fosså
F
F
Forland
K
K
Malde
S
S
Kvinnsland
I
I
Traaholt
B K
BK
Rossiné
O H
OH
Førde
D000328:Adult; D000368:Aged; D003376:Counseling; D003657:Decision Making; D005194:Family Practice / Q000592:standards; D006306:Health Surveys; D006801:Humans; D033181:Information Dissemination; D038622:Internationality; D008297:Male; D008403:Mass Screening; D015201:Meta-Analysis as Topic; D008875:Middle Aged; D009664:Norway; D017410:Practice Guidelines as Topic; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000517:prevention & control / Q000628:therapy; D013673:Technology Assessment, Biomedical; D014572:Urology / Q000592:standards
D017430:Prostate-Specific Antigen